Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.58 |
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | HTR2B | P41595 | 6/20 | 0.58 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | KDM1A | O60341 | 5/20 | 0.54 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13305511 | 1.00 | HTR2C (0.58) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL6130292 | 0.85 | HTR2C (0.57) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL6130290 | 0.85 | HTR2C (0.57) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL4587814 | 0.81 | HTR2C (0.53) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL24738380 | 0.80 | HTR2C (0.65) | HTR2CHTR2BHTR2ASLC9A1SLC6A3 | |
| SCHEMBL2090322 | 0.78 | HTR2C (0.62) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL2091037 | 0.78 | HTR2C (0.62) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL20009113 | 0.77 | HTR2C (0.53) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL24663868 | 0.77 | HTR2C (0.53) | HTR2CMAOBHTR2BHTR2AKDM1A | |
| SCHEMBL7959746 | 0.76 | ALOX5 (0.71) | HTR2CMAOBHTR2BHTR2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103857393-B | Cyclopropylamine is as LSD1 inhibitor | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| CN-101090723-A | Piperazine urea derivatives for the treatment of endometriosis | SCHERING AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| US-6573266-B1 | Compounds used for treating multitiple sclerosis and encephalomyelitis | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6555537-B2 | Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| US-6534509-B1 | Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | HTR2C 4486/4885MAOB 4014/4885HTR2B 4167/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | HTR2C 4405/4885MAOB 3858/4885HTR2B 4220/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | HTR2C 1897/4885MAOB 2478/4885HTR2B 561/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | HTR2C 4486/4885MAOB 4014/4885HTR2B 4167/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | HTR2C 1170/4885MAOB 2631/4885HTR2B 1976/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | HTR2C 1843/4885MAOB 965/4885HTR2B 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.